|
|
Office Locations:
|
300 Crescent Court, Suite 250
Dallas, TX 75201
Phone: 972-892-1700
| |
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
Established in 2008, Surveyor Capital is a global, multi-manager equities strategy and is one of Citadel Investment's three fundamental equities businesses. Surveyor's independent sector-aligned portfolio teams take a diligent, bottom-up investment approach. Citadel invests in companies in the Communications, Consumer, Energy, Financials, Healthcare, Industrials, Media and Entertainment, and Technology sectors.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
COMPANY STAGE | REVENUE |
Venture Capital | |
Seed Stage (includes "pre-seed," or concept stage) | No Revenue |
Early Stage | Minimal Revenue |
Growth Stage (also called Mid-stage) | $2M-$7M |
Expansion Stage (also called Late-stage) | $7M and greater |
Private Equity | |
Lower Middle Market | $10M-$249M |
Middle Market | $250M-$499M |
Upper Middle Market | $500M-$1B |
Large Cap | >$1B |
|
|
|
|
|
Name | |
| |
Title | |
|
Khalid Malik | |
| |
Portfolio Manager | |
Rich Falk-Wallace | |
| |
Portfolio Manager | |
Tariq Chaudhri | |
| |
Portfolio Manager | |
Todd Barker | |
| |
Head of Surveyor Capital | |
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
03/02/2021
|
Artiva Biotherapeutics
|
CA
|
$120,000,000
|
Series B
|
02/24/2021
|
Vividion Therapeutics
|
CA
|
$135,000,000
|
Series C
|
01/22/2021
|
Vera Therapeutics
|
CA
|
$80,000,000
|
Series C
|
01/19/2021
|
Verve Therapeutics
|
MA
|
$94,000,000
|
Series B
|
12/16/2020
|
Neuron23
|
CA
|
$113,500,000
|
Series A and B
|
11/09/2020
|
Decibel Therapeutics
|
MA
|
$82,000,000
|
Series D
|
10/06/2020
|
Talaris Therapeutics
|
MA
|
$115,000,000
|
Series B
|
09/17/2020
|
Palleon Pharmaceuticals
|
MA
|
$100,000,000
|
Series B
|
09/14/2020
|
ESCAPE Bio
|
CA
|
$73,000,000
|
Crossover Financing
|
08/27/2020
|
Kinnate Biopharma
|
CA
|
$98,000,000
|
Series C
|
08/10/2020
|
Dyne Therapeutics
|
MA
|
$115,000,000
|
|
08/07/2020
|
Aerovate Therapeutics
|
MA
|
$72,600,000
|
Series A
|
07/30/2020
|
Praxis Precision Medicines
|
MA
|
$110,000,000
|
Series C-1
|
07/24/2020
|
Olema Oncology
|
CA
|
$54,000,000
|
Series B
|
07/09/2020
|
VelosBio
|
CA
|
$137,000,000
|
Series B
|
07/02/2020
|
Bolt Biotherapeutics
|
CA
|
$93,500,000
|
Series C
|
07/02/2020
|
Annexon Biosciences
|
CA
|
$100,000,000
|
Venture
|
06/04/2020
|
Athira Pharma
|
WA
|
$85,000,000
|
Series B
|
03/30/2020
|
ElevateBio
|
MA
|
$170,000,000
|
Series B
|
03/03/2020
|
Pliant Therapeutics
|
CA
|
$100,000,000
|
Series C
|
|
|
|
|
|